Skip to main content
. 2021 Jun 22;125(5):679–686. doi: 10.1038/s41416-021-01415-9

Fig. 1. Progression-free survival according to ribociclib relative DI in patients receiving ribociclib with first-line endocrine treatment (FAS; investigator assessment)a.

Fig. 1

DI dose intensity, FAS full analysis set. aPooled data: patients from MONALEESA-2 (ribociclib plus letrozole group), MONALEESA-3 (ribociclib plus fulvestrant group) and MONALEESA-7 (ribociclib plus non-steroidal aromatase inhibitor group).